Article

Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive-10-01-2001
Volume0
Issue 0

Weak Bones, Strong Market

Driven somewhat by the HRT controversy and the growing population of postmenopausal women, the expanding osteo market made room for Eli Lilly's Evista (raloxifene), the first-in-class SERM. According to Dr. Leo Plouffe, Lilly's medical director of US women's health and reproductive medicine, the company has launched a series of clinical trials examining Evista's preventive effects against breast cancer and heart disease in women. And in another bold move, Lilly recently launched its groundbreaking Evista Alendronate Comparison (EVA) study, a head-to-head clinical trial comparing Evista with Fosamax for osteoporosis prevention and treatment and their relative efficacy in reducing risks of heart disease and breast cancer.

Articles in this issue
National Crisis Supercedes Coverage Debate
PBMs: Merck-Medco in the Hot Seat
National Crisis Supercedes Coverage Debate
image4-686-1409031567502.gif
A Five-Year Forecast: Clear Seas Ahead?
Weak Bones, Strong Market
Weak Bones, Strong Market
Approvals: Novartis’ Silver Lining
Pfizer and others Pitch In
Oncology: EMEA Approval Lags
Illegal Sales in India
Health Plan Premiums: Pharma Takes the Blame
image2-685-1409031572978.gif
Little Elan Becomes a Big Deal
A Song of Life

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Robert Lisicki
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Related Content
Spine BioPharma’s TGF-β Antagonist Misses Primary Endpoint in Phase III Degenerative Disc Disease Trial
August 4th 2025

Spine BioPharma’s TGF-β Antagonist Misses Primary Endpoint in Phase III Degenerative Disc Disease Trial

Don Tracy, Associate Editor
Despite missing the primary endpoint, SB-01 demonstrated durable clinical improvements and consistent results in the Phase III MODEL trial (NCT05516992), reinforcing its potential as a non-surgical treatment for chronic low back pain associated with degenerative disc disease.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 4th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Fatal Adverse Event Leads Allogene to Discontinue Novel Monoclonal Antibody, Adjust Cema-Cel Trial Protocol for Large B-Cell Lymphoma
August 4th 2025

Fatal Adverse Event Leads Allogene to Discontinue Novel Monoclonal Antibody, Adjust Cema-Cel Trial Protocol for Large B-Cell Lymphoma

Don Tracy, Associate Editor
Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined outpatient regimen aimed at accelerating enrollment and regulatory review in the Phase II ALPHA3 trial (NCT06500273).
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 4th 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
GAIN Therapeutics Ramps Up for Next Big Step in Parkinson’s Drug Development
August 4th 2025

GAIN Therapeutics Ramps Up for Next Big Step in Parkinson’s Drug Development

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for advancing a potential new treatment for Parkinson’s disease.
Peter Tummino
August 4th 2025

Computational Chemistry in Drug Discovery: Q&A with Dr. Peter Tummino

Mike Hollan
Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, high-resolution protein structures, and molecular mechanism of action, as well as optimizing target selection and small molecule design.